SAR 444559
Alternative Names: SAR-444559Latest Information Update: 21 Apr 2025
At a glance
- Originator Sanofi
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action CD38 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 31 Dec 2024 Discontinued - Phase-I for Autoimmune disorders in France (Parenteral), before December 2024
- 16 May 2023 SAR 444559 is still in Phase I trials for Autoimmune disorders in Australia
- 12 Feb 2023 Discontinued - Phase-I for Autoimmune disorders in Australia (Parenteral) (Sanofi pipeline; February 2023)